FDA Approves Vraylar (cariprazine) as an Adjunctive Treatment for Major
Depressive Disorder
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved Vraylar® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.
The most common side effects include difficulty moving or slow movements, tremors, uncontrolled body movements, restlessness and feeling like you need to move around, sleepiness, nausea, vomiting,
indigestion, constipation, feeling tired, trouble sleeping, increased appetite, and dizziness.
